These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 16759002)

  • 1. [Pharmacokinetic model for the enterohepatic circulation of mycophenolic acid].
    Jiao Z; Shen J; Zhong LJ; Yu YQ; Zhong MK
    Yao Xue Xue Bao; 2006 Mar; 41(3):272-6. PubMed ID: 16759002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus.
    Sherwin CM; Sagcal-Gironella AC; Fukuda T; Brunner HI; Vinks AA
    Br J Clin Pharmacol; 2012 May; 73(5):727-40. PubMed ID: 22053944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism-based enterohepatic circulation model of mycophenolic acid and its glucuronide metabolite: assessment of impact of cyclosporine dose in Asian renal transplant patients.
    Yau WP; Vathsala A; Lou HX; Zhou S; Chan E
    J Clin Pharmacol; 2009 Jun; 49(6):684-99. PubMed ID: 19386625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of mycophenolic acid and its glucuronide after a single and multiple oral dose of mycophenolate mofetil in Chinese renal transplantation recipients.
    Liang MZ; Lu YP; Nan F; Li YP
    Transplant Proc; 2006 Sep; 38(7):2044-7. PubMed ID: 16979994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enterohepatic circulation model for population pharmacokinetic analysis.
    Funaki T
    J Pharm Pharmacol; 1999 Oct; 51(10):1143-8. PubMed ID: 10579685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation.
    Mino Y; Naito T; Matsushita T; Otsuka A; Ushiyama T; Ozono S; Hishida A; Kagawa Y; Kawakami J
    Ther Drug Monit; 2008 Dec; 30(6):656-61. PubMed ID: 18978521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling.
    Cremers S; Schoemaker R; Scholten E; den Hartigh J; König-Quartel J; van Kan E; Paul L; de Fijter J
    Br J Clin Pharmacol; 2005 Sep; 60(3):249-56. PubMed ID: 16120063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease.
    Sherwin CM; Fukuda T; Brunner HI; Goebel J; Vinks AA
    Clin Pharmacokinet; 2011 Jan; 50(1):1-24. PubMed ID: 21142265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9.
    Jiao Z; Ding JJ; Shen J; Liang HQ; Zhong LJ; Wang Y; Zhong MK; Lu WY
    Br J Clin Pharmacol; 2008 Jun; 65(6):893-907. PubMed ID: 18279479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolic Acid and Its Metabolites in Kidney Transplant Recipients: A Semimechanistic Enterohepatic Circulation Model to Improve Estimating Exposure.
    Okour M; Jacobson PA; Ahmed MA; Israni AK; Brundage RC
    J Clin Pharmacol; 2018 May; 58(5):628-639. PubMed ID: 29329489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying degrees of renal function.
    Johnson HJ; Swan SK; Heim-Duthoy KL; Nicholls AJ; Tsina I; Tarnowski T
    Clin Pharmacol Ther; 1998 May; 63(5):512-8. PubMed ID: 9630824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of mycophenolic acid in Nagase analbuminemic rats: Evaluation of protein binding effects using the modeling and simulation approach.
    Yoshimura K; Yano I; Kawanishi M; Nakagawa S; Yonezawa A; Matsubara K
    Drug Metab Pharmacokinet; 2015 Dec; 30(6):441-8. PubMed ID: 26643991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of mycophenolic acid in live donor liver transplant patients vs deceased donor liver transplant patients.
    Jain A; Venkataramanan R; Sharma R; Kwong T; Abt P; Orloff M; Kashyap R; Tsoulfas G; Bozorgzadeh A
    J Clin Pharmacol; 2008 May; 48(5):547-52. PubMed ID: 18440919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients.
    Hummel M; Yonan N; Ross H; Miller LW; Sechaud R; Balez S; Koelle EU; Gerosa G;
    Clin Transplant; 2007; 21(1):18-23. PubMed ID: 17302587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited sampling strategy for simultaneous estimation of the area under the concentration-time curve of tacrolimus and mycophenolic acid in adult renal transplant recipients.
    Miura M; Satoh S; Niioka T; Kagaya H; Saito M; Hayakari M; Habuchi T; Suzuki T
    Ther Drug Monit; 2008 Feb; 30(1):52-9. PubMed ID: 18223463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacokinetics of mycophenolic acid in Chinese patients with liver transplant].
    Yu ZC; Chen H; Zhang WX; Zhou PJ; Zhou GW; Chen HZ
    Yao Xue Xue Bao; 2006 Dec; 41(12):1157-60. PubMed ID: 17290612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetic analysis of mycophenolic acid coadministered with either tasocitinib (CP-690,550) or tacrolimus in adult renal allograft recipients.
    Lamba M; Tafti B; Melcher M; Chan G; Krishnaswami S; Busque S
    Ther Drug Monit; 2010 Dec; 32(6):778-81. PubMed ID: 20926996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients.
    Naesens M; Kuypers DR; Streit F; Armstrong VW; Oellerich M; Verbeke K; Vanrenterghem Y
    Clin Pharmacol Ther; 2006 Nov; 80(5):509-21. PubMed ID: 17112807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.